Tenecteplase Drug Market Research Report, by Application (Myocardial Infarction, Stroke, DVT), Dosage(Intravenous Dosage, Intracatheter Instillation ), End-User (Hospitals & Clinics, Surgical Centers, Research Centers)-Forecast Till 2027
Tenecteplase Drug Market Scenario
Tenecteplase drug is an enzyme derived through recombinant DNA technology from a human cell line. This enzyme is used to treat thrombus (blood clots) it is also called as clot-busting drug. Tenecteplase is a bioengineered variant of the activase drug. The key factor responsible for influencing this market is the increasing cases of deep vein thrombosis, stroke, increase in blood pressure patient. According to the American Heart Association 2017, report every year almost 790,000 Americans have a heart attack. Coronary artery diseases are increasing day by day due to change in lifestyle. These factors enhance the tenecteplase drug market. However, factors such as the high cost of surgical procedures, allergic reaction, side effects associated with the drug are expected to restrict the market growth during the forecast period.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6401
Further, the report presented statistics like- Coronary heart disease (CHD) (43.8%) is the major cause of deaths attributable to cardiovascular disease (CVD) in the US, followed by stroke (16.8%), high BP (9.4%), heart failure (HF) (9.0%), and other CVDs (17.9%). Further, they projected by 2035, more than 130 million adults in the US population (45.1%) to have some form of CVD. The total costs of CVD are expected to reach USD 1.1 trillion in 2035. Stroke prevalence in adults is 2.7% in the United States. Similarly, as per CDC’s facts and statistics about stroke in the United States report 2017, every 140,000 Americans die every year due to stroke. Thus, the increasing rate of cardiovascular diseases increases the market growth of tenecteplase drug market in this region.
Key players
Some of the key players in the global tenecteplase drug market are Boehringer Ingelheim International GmbH, Genentec Inc., Gennova pharmaceutical, Rewine pharmaceuticals, Hisun USA, Emcure Pharmaceutical, Merck Ltd. and Crunchbase Inc., and others.
Segmentation
The global tenecteplase drug market is segmented on the basis of application, dosage and end users.
The tenecteplase drug market, by application segmented into myocardial infarction, stroke, deep vein thrombosis. The tenecteplase drug market, by dosage intravenous dosage and intracatheter instillation dosage. Intravenous dosage is sub-segmented into adult and geriatric and intracatheter instillation dosage is sub-segmented into adult, children, and adolescents weighing 30 kg, infants. On the bases of end-user, it is segmented into hospitals and clinics, surgical centers, research centers and other.
FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/tenecteplase-drug-market-6401
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services
